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Xanthine oxidoreductase regulates macrophage
IL1b secretion upon NLRP3 inﬂammasome
activation
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Activation of the NLRP3 inﬂammasome by microbial ligands or tissue damage requires
intracellular generation of reactive oxygen species (ROS). We present evidence that
macrophage secretion of IL1b upon stimulation with ATP, crystals or LPS is mediated by a
rapid increase in the activity of xanthine oxidase (XO), the oxidized form of xanthine
dehydrogenase, resulting in the formation of uric acid as well as ROS. We show that
XO-derived ROS, but not uric acid, is the trigger for IL1b release and that XO blockade results
in impaired IL1b and caspase1 secretion. XO is localized to both cytoplasmic and
mitochondrial compartments and acts upstream to the PI3K–AKT signalling pathway that
results in mitochondrial ROS generation. This pathway represents a mechanism for regulating
NLRP3 inﬂammasome activation that may have therapeutic implications in inﬂammatory
diseases.
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T
he inﬂammasome is key in regulating macrophage
interleukin (IL)-b secretion in response to pathogen-
associated molecular patterns (PAMPs) and damage-
associated molecular patterns (DAMPS). The NLRP3 inﬂamma-
some, composed of NLRP3, ASC and caspase1, can be activated
by soluble and particulate PAMPs (such as lipopolysaccharide
(LPS)) and DAMPs (such as urate and calcium crystals, nigericin
and adenosine triphosphate (ATP)), resulting in active caspase1
that cleaves proIL1b to the secreted p17kD form of IL1b. Multiple
pathways have been found to regulate inﬂammasome activation:
cellular and mitochondrial reactive oxygen species (ROS)1,
inﬂammasome translocation to the mitochondria by MAVS2,
cathepsin B release from phagolysosomes3, activity of the
cytosolic protein PKR4 and changing cytosolic levels of Kþ
(ref. 5) and Ca2þ (ref. 6). Among these pathways, ROS
generation is shared by a number of different inﬂammasome
triggers, such as LPS, urate crystals and ATP, but the source of
ROS has not been clearly established. Initial studies implicated
the NADPH oxidase (NOX) complex7,8, but more recent work
found that macrophages derived from knockout mice for the
NOX1, NOX2 or NOX4 component of this complex did not
impair IL1b secretion, and macrophages derived from patients
with chronic granulomatous disease due to mutations of this
complex were still capable of secreting IL1b in response to
DAMPs1,3,9. Mitochondrial ROS could be an alternative
intracellular source, and there is data linking mitochondrial
stress to ROS production as well as autophagy10,11.
Another potential source of cellular ROS is the enzyme
xanthine oxidoreductase (XOR), but its role has not been
investigated. XOR is a key enzyme in the catabolism of purines
into uric acid (UA) that is then further broken down to allantoin
in mammals that possess the enzyme uric oxidase (or uricase).
The xanthine oxidase (XO) form of XOR utilizes oxygen as a
substrate to break down hypoxanthine and xanthine to UA and
produces superoxide and hydrogen peroxide as part of the
reaction, and is expressed predominantly during cell stress or
upon immune activation. A number of clinical and experimental
studies have suggested that XOR activity has pro-inﬂammatory
effects and can mediate cardiovascular and endothelial dysfunc-
tion12,13, and inhibition of XOR by allopurinol has been shown to
reduce hypertension14 as well as improving cardiac function15.
UA itself also has both anti-inﬂammatory as well as pro-
inﬂammatory properties16, but the mechanisms linking XOR
activity to inﬂammation remain to be determined. Studies have
shown that UA plays a role in innate immune responses, and can
act as an adjuvant when released from dying cells, and take part in
plasmodium-induced inﬂammatory responses and the induction of
Th2 responses in asthma17–20. This raises the question which
product, ROS or UA, is responsible for these effects. Allopurinol,
an XOR inhibitor, decreased IL1b secretion in response to toll-like
receptor (TLR)7/8 stimulation or soluble hemozoin (HZ)
administration and inhibited urate production21,22. However,
other studies showed that the addition of uricase failed to block
inﬂammasome-dependent IL1b secretion, suggesting that other
mechanisms beside uric-acid production are involved7,23,24.
We hypothesize that XO-dependent generation of ROS
mediates NLRP3 inﬂammasome activation and thus, we studied
the role of XOR in DAMP- and PAMP-elicited IL1b responses.
Our results demonstrate that XO is a major source of ROS in
macrophages and is an important component of innate
inﬂammatory signalling.
Results
Crystalline activators require XO to induce IL1b secretion. We
previously demonstrated that basic calcium phosphate crystals
(including octacalcium phosphate (OCP)) elicit massive IL1b
secretion in primed bone-marrow-derived macrophages
(BMDMs) via an NLRP3-dependent mechanism in vitro25. We
showed that this process was accompanied by increased
intracellular urate levels and XO activity (as assessed by H2O2
production) (Fig. 1a). In vivo, elevated urate and XO activity
levels were also correlated to IL1b in peritoneal washes taken
from mice during OCP-induced peritonitis (Fig. 1a). Similarly,
Alum and HZ stimulation of BMDMs induced XO activity early
on during stimulation, at 2 h (Fig. 1b).
To demonstrate that XO activity is required for inﬂammasome
activation and IL1b secretion, we tested the effects of
XOR inhibition. Using short interfering RNA (siRNA) to impair
XOR expression (knockdown efﬁciency was determined to be
40±8.4%; Pr0.0001, t-test by quantitative reverse transcriptase
(qRT)–PCR, and 58±3.3%; Pr0.005, t-test by the XO
activity assay) we observed a signiﬁcant reduction in secreted
IL1b in primed and crystal-stimulated BMDM (Fig. 1c).
Treatment of primed BMDM with allopurinol or febuxostat
(two inhibitors targeting both XO and xanthine dehydrogenase
(XDH) forms)26,27, prior to crystal stimulation, yielded
similar results (Fig. 1d). Their inhibitory capacities were
similar to that observed with the ROS inhibitor apocynin
(Fig. 1d). As febuxostat also inhibited IL1b secretion in
human THP1 cells and primary human monocyte-derived
macrophages, we conﬁrmed that this was a general mechanism
(Fig. 1e; Table 1). Impaired phagocytosis was excluded, as
febuxostat did not affect the number of latex beads taken up by
Mf (percentage uptake 63.2±6.6% with febuxostat versus
68.5±1.8% in control cells).
Using the in vivo peritonitis model, we conﬁrmed XOR
inhibition by allopurinol in OCP-treated mice decreased IL1b
and urate levels in the peritoneal lavage, while cellular recruit-
ment remained unchanged (Fig. 1f).
XOR activity mediates caspase1 processing. As crystal-induced
IL1b secretion in macrophages relies on NLRP3 inﬂammasome
assembly and the formation of active caspase1, we examined the
role of XOR. We conﬁrmed that febuxostat reduced intracellular
caspase1 activity after OCP stimulation (non-treated:
176.63±5.811; febuxostat: 55.20±39.269 relative ﬂuorescence
units (RFUs)mg 1 of protein; Pr0.05, t-test). Experiments on
primed, but unstimulated BMDMs showed no decrease in the
intracellular pool of proIL1b after febuxostat treatment
(3,342.50±427.50 and 3,148.75±71.25 pgml 1, respectively) in
BMDM at 4 h. Similar results were found in THP1 cells (Fig. 1e).
Yet, febuxostat did impact the levels of processed caspase1 and
IL1b secreted from the cells (Fig. 1e). Taken together, these
results demonstrate that XOR plays an important role in the
generation of active caspase1, which allows for IL1b to be cleaved
and secreted outside the cell.
We tested the effects of febuxostat on OCP-induced IL1b
secretion by human macrophages. Using two different forms of
priming (LPS ultrapure and Pam3Cys), OCP crystals induced
IL1b release and this was signiﬁcantly impaired when febuxostat
was added (Table 1).
The effects of XOR are not mediated by urate. As UA can act as
an immune adjuvant17,28, we evaluated whether our responses
could be due to XOR generation of urate. Despite increased
intracellular urate, we did not detect any urate in the culture
supernatants, nor did extracellular uricase treatment affect
secreted IL1b levels, with the exception of monosodium
urate (MSU) stimulation. This was due to crystal degradation
(Fig. 2a).
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Figure 1 | XOR is involved in caspase1-dependent secretion of IL1b in macrophages stimulated with microcrystals. In vitro C57BL/6 BMDM (Pam3Cys
(P3C) or LPSup primed), and THP1 (PMA primed) were stimulated with OCP and MSU at 250 mgml 1, Alum-500mgml 1 and HZ-200mgml 1.
IL1b protein was measured by ELISA in supernatants; intracellular XO and UA measured on protein extracts by activity tests. (a) Upper panel: P3C primed,
OCP-stimulated BMDM. Lower panel: In vivo OCP-induced peritonitis. Levels of IL1b, XO and UA measured in peritoneal washes of individual mice.
(b) XO activity measured in LPSup primed, crystal-stimulated BMDM at 2 h. (c) IL1b measured in XOR siRNA, or control NegSiRNA-transfected BMDM
that were P3C primed. (d) BMDM were pretreated with XOR inhibitors (Allopurinol 250 gml 1, Febuxostat 200mM) and Apocynin (2.5mM), extracellular
IL1b protein levels quantiﬁed and expressed as percentage of stimulation of inhibitor-treated versus non-treated cells. (e) Protein sizes of proCaspase1
and proIL1b in cell extracts (CEs), and active IL1b in the supernatants (spts) by western blot, secreted IL1b and caspase1 by ELISA. (f) In vivo, mice
were pretreated with Allopurinol—500mg per mouse 30min prior to OCP-1mg per mouse or PBS control intraperitoneal injection. After 6 h,
peritoneal washes were obtained (two pooled experiments). Viable cells were counted and urate, and IL1b measured. Unless stated, experiments were
performed at 6 h and data are representative of at least two experiments. Results are expressed as mean±s.e.m. Signiﬁcance was determined at *Pr0.05,
**Pr0.01, ***Pr0.005 and ****Pr0.0001 by analysis of variance (b,d–f) or the t-test (a,c). NP, not performed; NS, not signiﬁcant.
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As the accumulated urate was retained within the cell, we
stimulated BMDM from transgenic uricase mice (intUOX-Tg)
with crystals28; no change in IL1b secretion was found (Fig. 2b).
This was despite the results that demonstrated that BMDM
derived from UOXTg mice did indeed overexpress the UOX gene
by qRT–PCR as compared with wild-type cells (41.3±6.01 versus
1±0.15, respectively, mean±s.e.m.). Uricase treatment in mice,
unlike experiments with allopurinol, failed to impact IL1b levels
produced in crystal-induced peritonitis (Figs 1f and 2c).
Finally, as very little is known about the effects of soluble
urate and urate transport on immune responses in macrophages,
we investigated this using BMDMs. Administration of high
concentrations of soluble urate to mimic conditions seen in
hyperuricemia in man (at 600 mM), ﬁltered to exclude
particulates, did not activate primed BMDM (Fig. 2a). The
capacity of BMDM to transport urate across the membrane was
also studied. We found BMDM had a limited capacity to take up
extracellular soluble urate in a C14 -radiolabelled assay
(Supplementary Fig. 1a). A positive control hURAT1-trans-
fected cell line conﬁrmed that our assay was indeed functional
(Supplementary Fig. 1a). Interestingly, BMDMs express a
speciﬁc urate transporter gene proﬁle, with only Glut9 being
expressed at a signiﬁcant level. No Urat1 and only weak
expression of Abcg2 was detected by qRT–PCR (Supplementary
Fig. 1b). Given these results, we did not investigate the protein
expression of urate transporters in BMDM. All together, these
results exclude a direct effect of soluble urate as the trigger for
IL1b release, and favours a mechanism involving XOR-
dependent ROS production.
XO mediates inﬂammatory signalling by ROS generation.
Previous studies and our own work demonstrated a role for ROS
scavengers in crystal-induced IL1b response, as NAC or
Table 1 | XOR inhibition impairs OCP-induced IL1b secretion in human macrophages.
Macrophages IL-1b secretion levels (pgml 1, mean±s.e.m.)
Subject Priming Stimulus Non-treated Febuxostat
1 Pam3Cys OCP 228.98±98.57 46.46±12.93**
LPSup OCP 281.07±38.06 22.32±24.41***
2 Pam3Cys OCP 1,039.75±35.61 467.83±36.43****
LPsup OCP 315.43±1.16 47.12±2.11**
3 Pam3Cys OCP 1,221.35±20.51 107.43±11.81****
LPsup OCP 48.23±8.17 Not induced
4 Pam3Cys OCP 913.21±8.21 954.74±37.85
LPsup OCP 377.27±125.29 20.72±21.78**
IL1b, interleukin-1b; M-CSF, macrophage colony-stimulating factor; OCP, octacalcium phosphate; PBMC, peripheral blood mononuclear cell; TLR, toll-like receptor; XOR, xanthine oxidoreductase.
Human PBMC-derived monocytes were differentiated into Mfs with 50 ngml 1 M-CSF. Cells were primed with TLR agonists, pretreated with febuxostat 200mM and stimulated with OCP 250mgml 1
for 6 h. IL1b in supernatants was measured. Results expressed as the mean±s.e.m. of independent stimulations. Statistical signiﬁcance determined at **Pr0.01, ***Pr0.005, ****Pr0.0001 by the t-
test.
0
30
60
200
1,400
2,600
3,800
Uricase
uns OCP MSU Alum Soluble
uric acid
600 μM
***
***
NS
33%
uns OCP MSU
0
1,000
2,000
3,000
4,000
5,000
Febuxo
ND ND ND
– + – – + – – + –– + –
Se
cr
. I
L1
β (
pg
 m
l–1
)
****
****
50%
****
****
– + – + – + – + – +
Wild type
IntUOX-Tg
HZ
Se
cr
. I
L1
β (
pg
 m
l–1
)
Vi
ab
le
 c
el
l
re
cr
u
itm
en
t
106
107
108
***
**
NS
0
**
***NS
NS
*****
**
Uricase
0
5
10
15
20
25
Ur
at
e 
(μM
)
100
50
IL
1β
 
(pg
 m
l–1
)
+– +–
PBS OCP
+– +–
PBS OCP
+– +–
PBS OCP
Figure 2 | Urate generated by XOR is not the mediator of inﬂammasome responses in crystal-stimulated macrophages. (a,b) In vitro C57BL/6 or
intUOX-Tg-derived BMDM (Pam3Cys primed), pretreated with uricase—10mgml 1 and XOR inhibitor febuxostat—200mM, were stimulated with OCP or
MSU at 250mgml 1, Alum-500mgml 1, HZ-200mgml 1 or soluble urate at 600 mM. Experiments were performed at 6 h; data are representative of at
least two experiments. (c) Mice were pretreated with uricase—20mg per mouse. OCP or PBS injected. After 6 h, peritoneal washes were obtained, viable
cells counted, and urate and IL1b measured in cell-free washes (two pooled experiments). Results are expressed as mean±s.e.m. Signiﬁcance was
determined at *Pr0.05, **Pr0.01, ***Pr0.005 and ****Pr0.0001 by analysis of variance. ND, not detectable; NS, not signiﬁcant.
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apocynin addition impaired IL1b release. Thus, we theorized
that XO could be the potential source of ROS in our model.
Two different assays were used. Signiﬁcant reductions of
superoxide were observed after febuxostat treatment using the
dihydroethidium (DHE) assay, similar to the reductions
observed with apocynin (Fig. 3a; Supplementary Fig. 2a), while
allopurinol reduced H2O2 generation by the luminol assay
(Fig. 3b).
The relative contribution of XO and XDH activities within the
cell was assessed using the pterin assay after crystal stimulation.
We found that crystal stimulation increased the percentage of
XO. XO activity was measured in the presence of pterin alone,
while total XOR activity was measured using both pterin and
methylene blue (that replaces the NADþ electron receptor29
(Fig. 4a). Cellular responses to XO-generated superoxide require
post-translational modiﬁcation of the protein, but this can be
coupled with increases in the intracellular protein pool. However,
no modulation in XOR at the RNA transcript or protein level was
observed (Fig. 4b,c). There was also no evidence of proteolytic
transformation from the native 145 kDa to the truncated 85-kDa
form by western blot (Fig. 4d). This suggests increased XO
activity is due to reversible modiﬁcation of XOR to generate the
XO form of the enzyme. In support of this, we found that
addition of the antioxidant dithiothreitol to BMDM lysates
resulted in a decreased percentage of XO activity relative to total
XOR activity in BMDM as compared with non-treated controls
(73.7 versus 17.9%, respectively). Altogether, these results suggest
that XO activity in crystal-stimulated BMDM was most likely due
to reversible sulfhydryl modiﬁcation of XDH to XO that does not
change the molecular weight of the protein.
XO induces mitochondrial ROS via the PI3K–AKT–mTOR
pathway. The PI3K–AKT–mTOR pathway is implicated in ROS-
dependent responses to ATP, HZ and basic calcium phosphate
crystals30–32. Activation of this pathway initiates a signalling
cascade that changes cellular metabolism, apoptosis, autophagy
and inﬂammatory responses. We conﬁrmed that crystals induced
phosphorylation of AKT in BMDM and THP1, and XOR
inhibition decreased the observed levels (Fig. 5c,d). The role of
the PI3K–AKT–mTOR pathway was further conﬁrmed, as
Ly294002, wortmannin, AKTx inhibitor and rapamycin all
signiﬁcantly decreased IL1b secretion in OCP-stimulated
BMDM (Fig. 5a,b). In addition, XO and the PI3K/AKT
pathway were upstream of mitochondrial ROS production, as
febuxostat, and Ly294002 signiﬁcantly decreased mitochondrial
ROS detected by mitoSOX ﬂuorescence in OCP-stimulated
BMDM (Fig. 5e). Using JC-10 to assess mitochondrial
depolarization, we conﬁrmed that febuxostat prevented OCP-
induced membrane changes (Fig. 5f). Speciﬁcity of mitochondrial
ROS detection by mitoSOX was veriﬁed using apocynin
(Supplementary Fig. 2).
Interestingly, although XOR co-localized to both the
mitochondria and the cytoplasm, OCP exposure did not affect
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the staining pattern (Fig. 6a). Further investigation saw
that XOR was present in both compartments, but with a
predominance of the XO form in the mitochondrial fraction.
Both the cytoplasmic and the mitochondrial fractions
were functional, and febuxostat inhibitable XOR activity
was found (Supplementary Fig. 3). Mitophagy and
autophagy negatively regulate inﬂammasome-mediated IL1b
secretion10,33,34. Thus, we tested whether XOR inhibition
changed the cell’s homeostatic balance to induce autophagic
vesicle formation, which would reduce the pool of
proIL1b available for cleavage. The degree of autophagy
remained unchanged after the treatment of primed,
unstimulated BMDM with febuxostat as detected by
immunocytochemistry using an antibody speciﬁc for the
lipidated type-II form of LC3B. Yet, signiﬁcant increases in
autophagy were observed after AKTx and rapamycin
administration (Fig. 6b).
These results imply that XO formation is essential for oxidative
stress generation, and inﬂammasome activation via the PI3K–
AKT–mTOR pathway, following exposure to crystals.
Soluble activators of the inﬂammasome activate XO. As the
inﬂammasome can be activated within macrophages following
exposure to soluble PAMPs and DAMPs, we evaluated whether
XOR was involved. Primed BMDM, stimulated with LPSc (crude
extract of LPS), induced signiﬁcantly more XO activity as com-
pared with unstimulated controls, and when febuxostat, NAC or
Ly294002 was added prior to stimulation there was a signiﬁcant
reduction in secreted IL1b (Fig. 7a,b). As with our in vivo crystal-
induced peritonitis model, we performed in vivo studies in mice
to conﬁrm our in vitro work. Febuxostat administration, prior to
LPSc injection, reduced the urate and IL1b detected in peritoneal
washes (Fig. 7c). Finally, IL1b secretion induced by LPS, ATP and
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Figure 5 | Crystal-mediated XOR activation induces the PI3K–AKT–mTOR pathway and mitochondrial ROS production. In vitro BMDM (Pam3Cys
primed), and THP1 cells (PMA primed) were pretreated with 200mM febuxostat, 10 mM Ly294002, 10 mM Wortmannin, 10mM AKTx, or Rapamycin
(Rapa), and stimulated with OCP or MSU at 250 mgml 1, or 500mgml 1 Alum. (a,b) IL1b protein secretion measured in BMDM. (c) Relative expression
levels determined by ELISA of phosphorylated (p-) AKT (ser473) over total AKT levels in BMDM at 1 h. (d) THP1 cell extracts analysed for phosphorylated
AKT (p-AKT) at ser473, and a-tubulin by western blot. Relative protein levels determined by band intensity quantiﬁcation, and given as p-AKT over
a-tubulin, normalized with unstimulated cells being 1. (e) Mitochondrial ROS detected by MitoSOX, results given as RFU at T¼ 60min over T¼0.
(f) Mitochondrial potential of BMDM was measured using the ratio of monomeric (Em525) to multimeric JC-10 (Em590). Experiments were performed at
6 h; data are representative of at least two experiments. Results are expressed as mean±s.e.m. Signiﬁcance was determined at *Pr0.05, **Pr0.01,
***Pr0.005 and ****Pr0.0001 by analysis of variance for all panels
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7555
6 NATURE COMMUNICATIONS | 6:6555 | DOI: 10.1038/ncomms7555 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
nigericin was markedly impaired after febuxostat or AKTx
treatment (Fig. 7d).
These results conﬁrm our hypothesis that XOR activation is
essential for inﬂammasome activation and IL1b cytokine
secretion.
Discussion
The formation of ROS by phagocytes is critical for bacterial
killing, but it can also regulate cellular signalling cascades during
immune activation35. The inhibition of NLRP3-inﬂamma-
some-mediated IL1b secretion by free-radical scavengers such
as apocynin demonstrates the importance of this signalling
pathway36. Multiple intracellular sources of ROS exist, including
NOX complexes, the mitochondria37 and last but not
least, through activity of the oxidase form of XOR. Although
it was initially thought that inﬂammasome ROS was generated
by NOX, this idea was refuted by evidence from studies
using human and mice cells deﬁcient for components of the
NOX complex.
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Our data showed that the XO form of XOR is the major source
of ROS in macrophages that mediates NLRP3 inﬂammasome
activation. XOR is an evolutionarily conserved, constitutively
expressed enzyme involved in purine degradation that catalyses
the conversion of hypoxanthine or xanthine to UA. It is a
homodimer; each 145-kDa subunit has three domains: an
N-terminal 20-kDa domain containing two Fe–S centres, a
central 40-kDa ﬂavin adenine dinucleotide domain and a
C-terminal 85-kDa molybdopterin-binding domain. XOR is
predominantly a NADþ -dependent dehydrogenase (XDH), but
upon oxidative stress, it can be converted to the oxygenase form.
Both forms generate UA, but the XO form also produces
superoxide and hydrogen peroxide. The conversion of XDH to
XO can be by irreversible proteolytic cleavage of the 145-kDa
protein to an 85-kDa form, or by reversible sulfhydryl modiﬁca-
tion that changes the electron acceptor sensitivity of the ﬂavin
adenine dinucleotide domain through tertiary structure con-
formational modiﬁcations38–40.
Our results show that XO inhibition attenuates NLRP3
inﬂammasome activation, as evidenced by impaired caspase1
and IL1b secretion in macrophages in vitro and in vivo. There was
no effect of febuxostat on activation of the AIM2 inﬂammasome
(Supplementary Fig. 4), indicating that this mechanism may be
speciﬁc for NLRP3 activation. We used XO inhibitors in our
studies rather than siRNA, as we could administer the inhibitors
after cellular priming, thus excluding that our results were to due
an effect on Mf priming via TLR stimulation. Although, mutated
and deﬁcient XOR mice exist, they die prematurely making
in vivo experimentation difﬁcult41,42.
We suggest that the conversion of XOR to XO occurs via
reversible oxidation of cysteine residues, rather than proteolytic
cleavage of the protein into the 85-kDa form, as we found no
change in the molecular weight of XOR when the inﬂammasome
was activated by OCP crystals, and because dithiothreitol
treatment of BMDM converted a large proportion of XO activity
to XDH. XOR protein was localized to the cytoplasm as well as to
the mitochondria by confocal microscopy, so both compartments
may participate in ROS generation. As there are no XO-speciﬁc
antibodies available, we cannot deﬁnitively conﬁrm that it is the
XO form that is found in both locations. However, cell
fractionation experiments showed that both cytoplasmic and
mitochondrial fractions had measurable XOR activities, in
support of our hypothesis.
We determined that XOR-dependent ROS also activates the
AKT–PI3K–mTOR pathway in macrophages30–32. Cellular
oxidative stress is linked to the AKT–PI3K–mTOR pathway.
ROS inactivates the regulatory subunit PTEN (phosphatase and
tensin homologue deleted on chromosome 10), which enables
downstream activation of AKT, and the mTOR complex 1 refs
43,44. In our in vitro stimulation experiments, febuxostat inhibited
the phosphorylation of AKT, reduced mitochondrial ROS and
impacted processing and IL1b secretion by caspase1. As autophagy
reduces inﬂammasome-dependent IL1b secretion and is negatively
regulated by the AKT pathway10,45–47, we wondered whether our
results were because febuxostat increases autophagy. Yet, we found
no evidence of increased autophagy when cells were exposed to
febuxostat and concluded that the observed responses were due to
impaired ROS generation. Furthermore, febuxostat did not
interfere with calcium ﬂux (Supplementary Fig. 5).
We also investigated whether it was UA, the other product of
XOR activity, that mediated cellular activation. UA crystals are
potent inﬂammasome activators, yet little is known about the
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effects of soluble urate on immune responses. Despite observing
high intracellular urate levels after crystal stimulation, IL1b
secretion remained high in cells from uricase transgenic
macrophages, or when extracellular uricase was added to the
culture system. Also, macrophages treated with soluble urate
failed to show augmented IL1b secretion, even at concentrations
seen in clinical hyperuricemia in man. When we combine these
results with the observation that there is no clear urate transport
mechanism in macrophage, this suggests to us that soluble UA is
not responsible for inﬂammasome activation. However, it is
possible that when large amounts of UA are released from dying
cells, urate crystals could be formed, which then activate the
inﬂammasome as a particulate stimulus via XOR activation. We
have attempted to conﬁrm this by polarizing light microscopy,
but were unable to detect urate crystals within dying cells or in
the supernatant.
Besides gout, hyperuricemia is also a risk factor for hyperten-
sion and cardiovascular disease48, but the mechanisms are not
well understood. High urate levels can be pro-inﬂammatory to
the endothelium and renal tubules16,48,49. Our current results
could explain these associations. We propose that hyperuricemia
is an indicator of increased XO activity that leads to enhanced
ROS formation and pro-inﬂammatory cell responses. This will
not only affect IL1b secretion from macrophages, but through its
actions on the PI3K–AKT pathway, affect other cellular
responses. These interactions could account for the associations
previously observed in epidemiological studies, and also why XO
inhibition by allopurinol has a beneﬁcial effect on hypertension
and stroke50–52.
On the basis of our results, we suggest that XOR inhibitors may
improve conditions that are linked to inﬂammasome activation,
such as atherosclerosis28,52,53. However, careful exploration of
their mechanism of action is needed, as UA can be an important
antioxidant in the circulation. Current XOR inhibitors inhibit
both the XDH and XO forms of XOR, and are used principally to
lower urate levels. To overcome this problem, the development of
an XO-speciﬁc inhibitor that would impact ROS but leave XDH
activity untouched is warranted. This would maintain urate levels
but decrease the oxidative stress-dependent pathology of chronic
inﬂammatory diseases.
Methods
Mice. C57BL/6 mice were purchased from Charles River. Intracellular uricase
transgenic-intUOX-Tg mice and littermate controls (on a C57BL/6 background)
were from K. Rock (University of Massachusetts, USA)18. All experiments and the
housing of the mice adhered to the guidelines set by the ‘Service de la
consommation et des affaires ve´te´rinaires du Canton de Vaud’ for the humane use
of laboratory animals with authorization from the state veterinarian. Female mice
used in experiments were 8–10 weeks of age.
BMDM preparation and maintenance of THP1 cells. Bone marrow cells were
incubated for 7 days on Petri dishes with 30% L929 conditioned media, 20% fetal
bovine serum (PAA) in Dulbecco’s modiﬁed Eagle’s media (Life Technologies) to
differentiate into BMDM. BMDM and THP1 cells were stimulated with complete
RPMI (cRPMI) media (Life Technologies) with 10% fetal bovine serum, 1% Hepes
(Life Technologies) and 1% penicillin–streptomycin (Sigma-Aldrich), or incom-
plete RPMI with 1% penicillin–streptomycin only).
Human monocytes and macrophage generation from healthy donors.
Peripheral blood was obtained from healthy donors after informed consent.
Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque (Life Tech-
nologies). Monocytes were puriﬁed by magnetic-associated cell sorting by negative
selection. Differentiation used 50 ngml 1 of recombinant human macrophage
colony-stimulating factor (R&D systems) in cRPMI.
XO inhibition and stimulation of cells. Sterile, pyrogen-free (r0.01 EUper
10mg—by Limulus amebocyte cell lysate assay) OCP, and MSU crystals were
synthesized as described previously54,55. Alum and Hz (Invivogen) were
resuspended in PBS and sonicated prior to use. Primary cells (BMDM and huMj)
were primed with 100 ngml 1 Pam3Cys or 20 ngml 1 ultrapure LPS–LPSup
(Invivogen) overnight or left unstimulated in cRPMI. THP1 cells were primed for
3 h with 300 ngml 1 phorbol myristate acetate (PMA). Inhibitors used were:
250 mgml 1 allopurinol (Sigma-Aldrich), 200mM febuxostat (Teijin Pharma Ltd.),
2.5mM apocynin (Sigma-Aldrich), 12.5mM NAC (Sigma-Aldrich), 20 mgml 1
rasburicase (Sanoﬁ), 10 mM Wortmannin (Sigma-Aldrich), 10 mM Ly294002
(Sigma-Aldrich), 10mM AKTx inhibitor (Calbiochem) and 50 nM rapamycin
(Sigma-Aldrich). To ensure that our results were due to the actions of the inhibitor
on the cell, our non-treated controls always contained equal quantities of the
resuspension vehicle of the inhibitors. For febuxostat, wortmannin, Ly294002 and
AKTx this was dimethylsulphoxide (DMSO). Cells were stimulated using
250 mgml 1 OCP and MSU, 500 mgml 1 Alum, 200 mgml 1 Hz and 1 mgml 1
crude LPS (Escherichia coli O111:B4—Sigma-Aldrich) for 6 h, unless stated
otherwise. Supernatants were collected, the cells harvested and protein or RNA
analysed.
XOR activity and UA determination. Cell lysates were tested for XO activity
(AAT Bioquest) and UA quantiﬁcation (Invitrogen) using ﬂuorescence assays. The
amount of ﬂuorescent resoruﬁn is directly proportional to the amount of H202
generated during the respective enzymatic reactions. Fluorescence was measured at
Ex540 Em590 cutoff 590. The manufacturer’s protocols were followed. The results
from the in vivo OCP peritonitis model were expressed in RFUs and the intra-
cellular XO levels in BMDM were expressed as nM H202 per mg protein per min.
The pterin assay to discriminate between XO and XDH activity was performed as
previously described29. Brieﬂy, cell lysates of BMDM were placed into two different
reaction mixes—one that measures XO activity using the conversion of 50 mM
pterin to isoxanthopterin, and the other that measures total XOR activity by using
methylene blue to replace NADþ as the electron receptor. Fluorescence was
measured at 345/390 nM. The results were calculated as the percentage of XO or
XDH activity against the total XOR activity.
Cytokine and XOR protein quantiﬁcation. Supernatants or protein lysates from
cells were assayed using the IL1b enzyme-linked immunosorbent assay (ELISA) kit
(eBioscience). XOR protein quantiﬁed using the anti-mouse XDH ELISA kit
(USCN life sciences). All manufacturers’ protocols were followed. The results were
read at 450 nm using the Spectrax M5e (Molecular Devices). Caspase1 activity was
measured using a ﬂuorometric activity test that measures the amount of free
7-amino-4-triﬂuoromethylcoumarin (AFC) that has been cleaved from YVAD-
AFC by active caspase1 within the cell. Fluorescence was detected at Ex 400 nm Em
505 nm (Biovision Inc.). Human caspase1 was measured by ELISA (eBioscience).
In vivo experiments. Female C57BL/6 mice were treated with Allopurinol 500 mg
per mouse, Febuxostat 1mM or rasburicase 20 mgml 1 or a DMSO vehicle
control prior to injection with OCP crystals or LPSc in the peritoneal cavity. PBS
alone was administered as a control. After 6 h, mice were sacriﬁced, the peritoneal
cavity washed with PBS and then analysed for urate, extracellular XO activity and
IL1b by ELISA (eBioscience).
SiRNA knockdown of XOR. BMDM were transfected using the Amaxa nucleo-
fector (Lonza AG). BMDM were transfected using either XOR-speciﬁc siRNA 50-
CCGAGGATTTCAAACCTTTA-30 or control siRNA (proprietary sequence-
SI03650318) at 300 nM (Qiagen). Knockdown efﬁciency was determined by
quantitative real-time PCR and the XO activity assay.
Western blot. Cells were lysed in 0.5% NP-40 lysis buffer of 150mM NaCl, Tris-
HCl with EDTA-free protease inhibitor cocktail (Roche), and resuspended with
Lammeli buffer. Blots were prepared using polyacrylamide gels, and nitrocellulose
membranes using the Bio-Rad II system. Antibodies used were anti-human IL1b
(1:1,000 dilution, Cell Signaling Technology), anti-human procaspase-1 (1:500
dilution, gift from R. Solari), Phospho-AktSer473 (1:2,000, Cell Signaling Technol-
ogy) or a-tubulin (1:2,000 dilution, Sigma-Aldrich), anti-human XDH antibody
(1:2,000 dilution, xAbcam) and anti-rabbit-horseradish peroxidase (HRP), and
anti-mouse HRP (1:2.000 dilution, Jackson laboratories). Blots were revealed using
the Las2000 system with the Westbright Iris ECL reagent (Advansta). Subcellular
fractions were blotted with Anti-XOR (H-110, Santa Cruz Biotechnology, at 1:250
dilution), anti-Tom20 (FL-145, Santa Cruz Biotechnology, at 1:500 dilution) and
anti-a-tubulin (Sigma, at 1:5,000 dilution). Images were cropped for ﬁgure pre-
sentation. Complete images are available as Supplementary Figs.
ROS assays. Luminol—100 nM and HRP—5UIml 1 (Sigma-Aldrich) was added
concurrently to the stimuli and luminescence measured after 60min using the
Tecan M200. Results were expressed as relative luminescence units. For DHE and
MitoSOX experiments, reagents were resuspended in DMSO and cells were loaded
with DHE or mitoSOX (Invitrogen) at 5 mM. Fluorescence was determined at Ex540
Em590. Results expressed as RFUs at end point minus T¼ 0. Experiments used
opaque tissue culture-treated 96-well plates (Greiner Bio-One), and performed in
HBSS (Life Technologies).
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Quantiﬁcation of AKT phosphorylation. AKT phosphorylation was measured in
cell lysates using the InstantOne ELISA (eBioscience). The manufacturer’s
instruction was followed. Results expressed as the ratio of phospho-AKTSer473
versus total AKT.
Mitochondrial membrane potential assay using JC-10. JC-10 enters the mito-
chondria, where it is retained in multimeric form while the compartment remains
polarized. During membrane depolarization the JC-10 is converted to the mono-
meric form. Brieﬂy, JC-10 (AAT Bioquest) was added to cells coated onto a black
microtiter plate. Cells were then stimulated as above in the presence of JC-10. After
5min, the ﬂuorescence of the multimeric form (Ex540/590) and monomeric form
(Ex490Em525) were measured. Results were expressed using the ratio of 525/590.
Calcium ﬂux measurement. BMDM were primed with Pam3Cys O/N, washed
and loaded with Fluo-4 (Ca2þ -sensitive ﬂuorometric probe) for 1 h at 37 C in
presence of febuxostat or EDTA (as a positive control for calcium ﬂux inhibition).
Baseline ﬂuorescence was measured at 480 nm/520 nm. After stimulation with
MSU crystals, ﬂuorescence intensity was measured at 15 s interval over 15min.
Subcellular fractionation and western blot. Cellular fractionation of BMDM was
performed as previously described1. (Brieﬂy, BMDM were harvested, resuspended
in hypotonic buffer (100mM sucrose, 10mM HEPES and 1mM EDTA) and
passed through a 30-G needle and syringe, 1 in 12 volumes of hypertonic buffer
(1.78M sucrose, 10mM HEPES and 1mM EDTA) was added to homogenate, then
centrifuged at 700g and the supernatant harvested as cytoplasmic fraction.) The
precipitated crude mitochondrial fraction was washed, and resuspended with
isolation buffer (250mM sucrose, 10mM HEPES and 1mM EDTA). Protein was
quantiﬁed using the bradford colorimetric assay (BCA) method (Bio-Rad
laboratories). Equal protein quantities of the cytoplasmic and mitochondrial
fractions were loaded on to an SDS–polyacrylamide gel electrophoresis gel.
Microscopy experiments. To study autophagy, BMDM were stimulated on glass
microscope slides as above, ﬁxed with 98% methanol for 10min at  20 C and
permeabilized with 1 PBS and 0.5% Triton X-100 (Sigma-Aldrich). Cells were
incubated overnight with LC3B antibody (diluted 1/400 Cell Signaling) in antibody
diluent (BD Biosciences) and then stained with biotinylated anti-rabbit antibody
(Vector) followed by streptavidin-TRITC (AbD Serotec). Slides were mounted with
ProLong Gold Antifade Reagent with 40 ,6-diamidino-2-phenylindole (Life technol-
ogies). Images were taken using Upright Confocal Microscope Leica SP5 Tandem
and visualized at  1,000 magniﬁcation. Quantiﬁcation of autophagy was performed
using ImageJ on all experimental conditions. Brieﬂy, the corrected total cell ﬂuor-
escence was calculated for each cell present within a ﬁeld of view, and two inde-
pendent ﬁelds of view were analysed with at least 18 cells measured in total.
Corrected total cell ﬂuorescence was calculated by measuring the integrated ﬂuor-
escence density of the area of the cells—(the area of the cell the mean ﬂuorescence
of the background). The results of all of the individual cells were pooled to give the
mean and s.e.m. for each condition. This quantiﬁcation was performed in ImageJ.
Colocalization experiments were performed with BMDM adhered to glass
microscope slides and stimulated as above. Cells were stained with Mitotracker Red
(Life Technologies) and ﬁxed with 4% paraformaldehyde for 20min at RT. Cells
were permeabilized with 1x PBS and 0.5% Triton X-100 (Sigma-Aldrich), and
incubated overnight with anti-XOR Ab (5 ugml 1, Santa Cruz Biotechnology Inc)
in antibody diluent (BD Biosciences) followed by incubation with biotinylated anti-
rabbit antibody (Vector) and then streptavidin-FITC (eBiosciences). Slides were
mounted with ProLong Gold Antifade Reagent with 40 ,6-diamidino-2-
phenylindole (Life technologies). Images were taken using Upright Confocal
Microscope Leica SP5 Tandem and visualized at  630 magniﬁcation.
UA uptake assay. BMDM were incubated with 167mM of 14C UA in uptake
buffer (125mM sodium gluconate, 4.8mM potassium gluconate, 1.2mM potas-
sium phosphate, monobasic, 1.2mM magnesium sulfate, 1.3mM calcium gluco-
nate, 5.6mM glucose, 25mM Hepes, pH 7.3—all purchased from Sigma-Aldrich)
for 20min. Ultima Gold scintillation ﬂuid (PerkinElmer) was added and incubated
2 h for complete cellular lysis. Plate was read on a top count scintillation counter.
Results were expressed as the radioactive counts per minute. Cell viability was
controlled by Cell Titer Glo reagent (Promega).
PCR and quantitative real-time PCR. Brieﬂy, cells were placed into Trizol
(Invitrogen), RNA was extracted using the DirectZol RNA extraction kit
(Zymoresearch) and reverse transcribed into complementary DNA using
Superscript II (Invitrogen). Relative expression levels of RNA transcripts were
determined using gene-speciﬁc primers, SYBR green and the LightCycler 480
system (Roche). Gene-speciﬁc primers were Tata-binding protein (Tbp): 50-CCG
TGAATCTTGGCTGTAAAC-30 and 50-TCCAGAACTGAAAATCAACGC-30 ;
Gapdh: 50-CTCATGACCACAGTCCATGC-30, 30-CACATTGGGGGTAGGAAC
AC-50 ; Urat1: 50-ACACAGCCAGTCTCTTGATGGAGTG-30 , 30-CCGTGATGAG
CCAGCGTGCC-50 ; Abcg2: 50-ACCAGTGTTTTTCCAGTGTGTCAGC-30, 30-TC
CACCGTCTTCTTCAGTCCTAACA-50 ; Glut9: 50-GGGGCAGAGCCTGCAAGG
TG-30 , 30-ACAGGTGACCCCTGCCACCC-50; XOR: 50-TAGAAGAAAGT
TGGGGCTGTGCGG-30 and 50-AGGAGCAGATGGGGGTCAAGCAG-30 .
Relative expression levels of genes of interest were calculated using 2DDCT method
with Tbp, and Gapdh as reference genes.
Graphical representation and statistical analyses. Figures and statistics were
generated by Graphpad prism version 6. In vitro experiments were performed in
replicate. Results expressed as mean and s.e.m. Statistical signiﬁcance determined
using two-tailed parametric t-tests or analysis of variance.
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